Search Results
T Cell Engager Antibodies – focus on Hematological Malignancies | Presented by Dr. John Kuruvilla
CAR-T vs bispecific antibodies for lymphoma
Panel Discussion | Dr. Marcus Butler, Dr. Naoto Hirano, Dr. John Kuruvilla and Dr. Guy Ungerechts
CCH-QC Montréal 2017: Dr. John Kuruvilla - Hodgkin's Lymphoma
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, i...
CARE Update in Hodgkin's Lymphoma by Dr. John Kuruvilla (Princess Margaret Cancer Centre)
John Kuruvilla | EHA 18 | SADAL clinical trial in DLBCL
Bispecific T-cell engaging therapy for adult ALL
Dr. Michael Chu on CC-93269, a bispecific T-cell engager (BiTE) targeting BCMA and CD3, shows...
BiTE® Immunotherapy: The Next Generation of Cancer Treatment
Dr. John Kuruvilla invites you to the CARE Congress on Biosimilars on April 6th!
Update on selinexor for myeloma and large cell lymphomas
